ASH's nutraceuticals business provides nutrition product producers with a diverse selection of active ingredients and formulation aids.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors with an interest in Chemical - Specialty stocks have likely encountered both Ashland (ASH) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ashland's (ASH) Q3 sales are adversely impacted by reduced Life Sciences volumes and weaker pricing.
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ashland (ASH) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.23 per share a year ago.
Here is how Ashland (ASH) and Fortuna Mining (FSM) have performed compared to their sector so far this year.
Ashland (ASH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Ashland (ASH) and Novozymes A/S (NVZMY). But which of these two stocks presents investors with the better value opportunity right now?
Investors looking for stocks in the Chemical - Specialty sector might want to consider either Ashland (ASH) or Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?
Here is how Aris Mining Corporation (ARMN) and Ashland (ASH) have performed compared to their sector so far this year.